{"id":531924,"date":"2021-08-27T07:33:14","date_gmt":"2021-08-27T11:33:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/"},"modified":"2021-08-27T07:33:14","modified_gmt":"2021-08-27T11:33:14","slug":"medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/","title":{"rendered":"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays"},"content":{"rendered":"

\nPolyrizon\u2019s formulations previously demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells
\n<\/h2>\n
\n

\n OMER, Israel, Aug. 27, 2021 (GLOBE NEWSWIRE) — <\/strong>\u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, presented pre-clinical data showing that its Capture and Contain (C&C\u2122) platform technology has the potential to reduce the risk of an infection with Influenza virus H1N1 and may potentially also treat additional Cold viruses.<\/p>\n

Data from Polyrizon\u2019s cell-culture study confirms that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the influenza virus H1N1, a subtype of influenza A virus (a communicable viral disease), which causes upper, and potentially, lower respiratory tract infections in the host it infects, resulting in symptoms such as nasal secretions, chills, fever, decreased appetite, and possibly lower respiratory tract disease.<\/p>\n

Polyrizon tested several formulations of its lead platform against Influenza virus H1N1. In these studies, the products candidates\u00a0demonstrated high efficacy by preventing the influenza virus from affecting epithelial host cells and inhibit cells death.<\/p>\n

Polyrizon\u2019s new product candidate protects the nasal cavity and the respiratory tract and by that preventing the virus from colonizing in the upper respiratory and may decrease the viral load and facilitate the immune system to control the virus more effectively.<\/p>\n

Polyrizon\u2019s product candidate showed a promising safety profile in a cell toxicity studies, together with broad spectrum activity against different viruses as demonstrated in previous study against human corona virus 229E.<\/p>\n

These pre-clinical data highlight the Capture and Contain (C&C\u2122) impact of Polyrizon\u2019s product line that can be extended against Flu and Cold viruses and a variety of different respiratory viruses.<\/p>\n

\n About Medigus<\/strong>\n <\/p>\n

Medigus is traded on the Nasdaq Capital Market. To learn more about the company\u2019s advanced technology, please visit\u00a0http:\/\/www.medigus.com\/investor-relations<\/p>\n

\n Cautionary Note Regarding\u00a0Forward Looking Statements<\/strong>\n <\/p>\n

\n This press release may contain statements that are \u201cForward-Looking Statements,\u201d which are based upon the current estimates, assumptions and expectations of Medigus\u2019 management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cenvision,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201ccontemplate\u201d and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words<\/em>
\n . For example, Medigus uses forward looking statements when describing <\/em>
\n conclusions from <\/em>
\n Polyrizon\u2019s<\/em>
\n pr<\/em>
\n e<\/em>
\n -clinical<\/em>
\n study<\/em>
\n , the influence of <\/em>
\n Polyrizon\u2019s<\/em>
\n product <\/em>
\n candidate <\/em>
\n on the viral load and the immune system, the product <\/em>
\n candidate\u2019s <\/em>
\n safety profile and its <\/em>
\n preventative effect<\/em>
\n . These<\/em>
\n forward-looking statements represent Medigus\u2019 expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Medigus\u2019 activity to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus and <\/em>
\n Polyrizon<\/em>
\n are discussed in detail in the Medigus\u2019 filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether <\/em>
\n as a result of<\/em>
\n new information, future developments or otherwise. Neither Medigus nor its shareholders, <\/em>
\n officers<\/em>
\n and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus\u2019 securities. Nothing in this press release should be deemed to be medical or other advice of any kind\u00a0<\/em>\n <\/p>\n

\n Contact (for media only)<\/strong>\n <\/p>\n

Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com<\/a><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Polyrizon\u2019s formulations previously demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells OMER, Israel, Aug. 27, 2021 (GLOBE NEWSWIRE) — \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, presented pre-clinical data showing that its Capture and Contain (C&C\u2122) platform technology has the potential to reduce the risk of an infection with Influenza virus H1N1 and may potentially also treat additional Cold viruses. Data from Polyrizon\u2019s cell-culture study confirms that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the influenza … <\/p>\n

Continue reading “Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-531924","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Polyrizon\u2019s formulations previously demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells OMER, Israel, Aug. 27, 2021 (GLOBE NEWSWIRE) — \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, presented pre-clinical data showing that its Capture and Contain (C&C\u2122) platform technology has the potential to reduce the risk of an infection with Influenza virus H1N1 and may potentially also treat additional Cold viruses. Data from Polyrizon\u2019s cell-culture study confirms that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the influenza … Continue reading "Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-27T11:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays\",\"datePublished\":\"2021-08-27T11:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/\"},\"wordCount\":687,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/\",\"name\":\"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==\",\"datePublished\":\"2021-08-27T11:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/","og_locale":"en_US","og_type":"article","og_title":"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays - Market Newsdesk","og_description":"Polyrizon\u2019s formulations previously demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells OMER, Israel, Aug. 27, 2021 (GLOBE NEWSWIRE) — \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, presented pre-clinical data showing that its Capture and Contain (C&C\u2122) platform technology has the potential to reduce the risk of an infection with Influenza virus H1N1 and may potentially also treat additional Cold viruses. Data from Polyrizon\u2019s cell-culture study confirms that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the influenza … Continue reading \"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-27T11:33:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays","datePublished":"2021-08-27T11:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/"},"wordCount":687,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/","name":"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==","datePublished":"2021-08-27T11:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNjE5OSM0Mzc4MDE1IzUwMDA2NDMzMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-technology-found-effective-against-influenza-virus-h1n1-in-cell-culture-assays\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medigus: Polyrizon\u2019s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/531924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=531924"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/531924\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=531924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=531924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=531924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}